User profiles for Derk Jan A. de Groot
 | Derk Jan de GrootMD PhD, Medical oncologist, University Medical Center Groningen Verified email at umcg.nl Cited by 3675 |
[HTML][HTML] A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
…, EGE de Vries, DJA de Groot - Pharmacology & …, 2019 - Elsevier
Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to cancer.. For
use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of …
use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of …
Theranostics using antibodies and antibody-related therapeutics
KL Moek, D Giesen, IC Kok, DJA de Groot… - Journal of Nuclear …, 2017 - Soc Nuclear Med
In theranostics, radiolabeled compounds are used to determine a treatment strategy by
combining therapeutics and diagnostics in the same agent. Monoclonal antibodies (mAbs) and …
combining therapeutics and diagnostics in the same agent. Monoclonal antibodies (mAbs) and …
[HTML][HTML] Molecular imaging biomarkers for immune checkpoint inhibitor therapy
Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over
the past few years. ICIs offer an alternative treatment strategy by exploiting the patients' …
the past few years. ICIs offer an alternative treatment strategy by exploiting the patients' …
Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer–Results of the international …
…, I Edhemovic, AMR Cervantes, DJA De Groot… - Radiotherapy and …, 2020 - Elsevier
Background Preoperative chemoradiotherapy (CRT) followed by total mesorectal excision is
widely accepted as the standard of care for high-risk rectal cancer. Adjuvant chemotherapy …
widely accepted as the standard of care for high-risk rectal cancer. Adjuvant chemotherapy …
[HTML][HTML] Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal …
…, S Kruijff, LB Been, RJ Van Ginkel, DJA De Groot… - Bmc Cancer, 2019 - Springer
Background Upfront cytoreductive surgery with HIPEC (CRS-HIPEC) is the standard treatment
for isolated resectable colorectal peritoneal metastases (PM) in the Netherlands. This …
for isolated resectable colorectal peritoneal metastases (PM) in the Netherlands. This …
Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition
…, BJ Kroesen, C Roozendaal, DJA de Groot… - …, 2016 - academic.oup.com
! The Author 2016. Published by Oxford University Press on behalf of the British Society for
Rheumatology. All rights reserved. For Permissions, please email: journals. permissions@ …
Rheumatology. All rights reserved. For Permissions, please email: journals. permissions@ …
Perioperative systemic therapy vs cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases: a …
…, HMW Verheul, S Kruijff, DJA De Groot… - JAMA …, 2021 - jamanetwork.com
Importance To date, no randomized clinical trials have investigated perioperative systemic
therapy relative to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS…
therapy relative to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS…
Self‐Targeted Co‐Delivery of an Antibiotic and a Cancer‐Chemotherapeutic from Synthetic Liposomes for the Treatment of Infected Tumors
…, Y Ren, TG van Kooten, DJA de Groot… - Advanced Functional …, 2023 - Wiley Online Library
Intra‐tumor bacteria promote tumor growth and inactivate cancer‐chemotherapeutics, causing
poor treatment prognoses. Combined administration of cancer‐chemotherapeutics and …
poor treatment prognoses. Combined administration of cancer‐chemotherapeutics and …
Phase II study (KAMELEON) of single‐agent T‐DM1 in patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma
…, J Tabernero, L Gianni, E Voest, DJA de Groot… - Cancer …, 2023 - Wiley Online Library
The antibody‐drug conjugate trastuzumab emtansine (T‐DM1) is approved for human
epidermal growth factor receptor 2 (HER2/ERBB2)–positive breast cancer. We aimed to study …
epidermal growth factor receptor 2 (HER2/ERBB2)–positive breast cancer. We aimed to study …
Proteasome inhibitor MG132 sensitizes HPV‐positive human cervical cancer cells to rhTRAIL‐induced apoptosis
…, AGJ van der Zee, DJA de Groot… - … journal of cancer, 2006 - Wiley Online Library
In cervical carcinogenesis, the p53 tumor suppressor pathway is disrupted by HPV (human
papilloma virus) E6 oncogene expression. E6 targets p53 for rapid proteasome‐mediated …
papilloma virus) E6 oncogene expression. E6 targets p53 for rapid proteasome‐mediated …